Navigation Links
Pier Pharmaceuticals Names Peter Letendre as Chief Executive Officer, President and Director
Date:12/17/2010

LOUISVILLE, Colo., Dec. 17, 2010 /PRNewswire/ -- Pier Pharmaceuticals Inc.(formerly known as Steady Sleep Rx Co.), a clinical stage biopharmaceutical company focused on the treatment of sleep related breathing disorders (SRBDs), announced today the appointment of Peter W. Letendre, Pharm.D. as its CEO & President and his election to the Board of Directors.

As CEO and President, Dr. Letendre will be responsible for spearheading the clinical, regulatory, IP and strategic direction of the company. Based on data from a pilot proof of concept (POC) study in patients with obstructive sleep apnea (OSA), Dr. Letendre's initial efforts will be to raise additional capital to continue the clinical development of its lead compound, PP-001 for the treatment of OSA.

"Pete brings a wealth of successful experience across all aspects of the pharmaceutical business," said Ken Cohen, Chairman of the Board of Pier.  "The Board is confident he'll be an outstanding and effective leader as we move forward in the development of our sleep apnea drug candidate and the growth of the company."  

Dr. Letendre is an accomplished pharmaceutical industry executive and leader with over 21 years of a proven track record in commercialization, business strategy and management in both large and developing pharmaceutical and biopharmaceutical companies. Prior to joining Pier Pharmaceuticals, Pete was the President and Founder of Greyhound Pharmaceutical Consulting, Chief Commercial Officer at Replidyne, Inc. and Divisional Vice-President and General Manager of the hypertension and infectious disease franchises at Abbott Laboratories. Before joining Abbott Laboratories in 2002, Pete spent twelve years at SmithKline Beecham/GSK in commercial roles of increasing responsibility and scope in the therapeutic areas of psychiatry, neurology, infectious disease and endocrinology/diabetes. Under Pete's leadership and strategic direction, three of the franchises Pete was respo
'/>"/>

SOURCE Pier Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
3. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
4. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
5. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
6. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
7. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
8. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
9. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
10. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
11. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... (PRWEB) July 11, 2014 Cayenne ... company specializing in the soft tissue reconstruction segment, ... Anchor System for surgeries involving the shoulder and ... through a novel, inserter-controlled deployment method. The unique ... partial deployment, anchor pull-out, or anchor displacement (also ...
(Date:7/10/2014)... Understanding the need for better quality and ... gap that currently exists in this area, ChanTest has ... of validated ion channel and GPCR cell lines. ... ion channels control many critical physiological functions throughout the ... potential to treat a variety of human diseases. ...
(Date:7/10/2014)... 10, 2014 OMICS Group’s 5th International ... 18-20 August, 2014 at Double Tree by Hilton Beijing, ... developments in Analytical & Bioanalytical research methods only to ... on this occasion, Dr. Srinubabu Gedela, MD of OMICS ... is a remarkable one in bringing a unique and ...
(Date:7/10/2014)... ST. PETERSBURG, Russia , July 10, 2014 /PRNewswire/ ... the Russian Federation Dmitry Medvedev , presented ... a biopharmaceutical company BIOCAD . The Company is ... the scope of MabNext project BIOCAD develops a number ... of cancer and autoimmune diseases. The ceremony took place ...
Breaking Biology Technology:Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2
... as heat during the production of electricity could ... synthesized via a technique developed by researchers with ... National Laboratory (Berkeley Lab) and the University of ... of this technology include DOEs hydrogen fuel cell-powered ...
... HealthCare Technologies,Ltd., (the "Company") today announced that ... the Staff of the Listing Qualifications Department,(the "Staff ... indicated,that because the Staff believes that the Company,s ... on December 31, 2007, constituted a,reverse merger, the ...
... Seven Summits Research issues,PriceWatch Alerts for key stocks., ... http://www.iotogo.com/s/011008B (Note: You may have to ... key.), Today,s PriceWatch Alerts cover the following stocks: ... Co., Inc. (NYSE: MER ), DryShips, Inc. (Nasdaq:,DRYS), ...
Cached Biology Technology:Feeling the heat 2Feeling the heat 3Feeling the heat 4HealthCare Technologies Ltd. (NASDAQ: HCTL) Announces Receipt of NASDAQ Delisting Notice 2Seven Summits Research Releases Alerts on XOM, MER, DRYS, CSC, and PDLI 2Seven Summits Research Releases Alerts on XOM, MER, DRYS, CSC, and PDLI 3
(Date:7/10/2014)... 2, 2014 NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company ... Gino Pereira was interviewed on July 1 st ... Tampa Florida . Mr. Pereira discusses the company,s next ... and how the Wocket™ aims to replace a traditional ... Cedric Harris tells Gino he has never heard ...
(Date:7/10/2014)... July 7, 2014 According to ... "Electronic Access Control Systems Market Global Forecast, Market Share, ... global Electronic Access Control systems market was valued at ... grow at a CAGR of 12.6% from 2014 to ... million in 2019. Browse the full Electronic ...
(Date:7/10/2014)... to the large, mainly tropical flowering plant family Melastomataceae (Meadow ... family rely on bees for their pollination. Only about 100 ... The flowers of Axinaea appear in clusters of ... the different species are pink, yellow, orange or red. The ... colours of their bulbous appendages. The pollination mechanism of ...
Breaking Biology News(10 mins):Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 4Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 2Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 3Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 4Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 5Novel type of bird pollination mechanism discovered in South America 2
... Men who develop breast cancer are often not treated ... treatment becomes difficult, new results show. Although most ... 1% of cases, Dr. Marina Garassino from the Orion ... organized by the European Society for Medical Oncology. ...
... beyond, humans have always wanted to fly. First ... unfailingly ended in disaster. No workable flying machines ... today there is little comparison between a top of ... similar flight patterns. In an era in which ...
... Diversity among the ancestors of such marine creatures as ... rise beginning 144 million years ago with no clear ... This contradicts previous work showing dramatic increases beginning 248 ... diversity. "Some of the time periods in the ...
Cached Biology News:Treatment delays result in poor outcomes for men with breast cancer 2Want to fly? Don't copy the birds and the bees 2Species have come and gone at different rates than previously believed 2Species have come and gone at different rates than previously believed 3
... (patent pending) was developed using a protein engineering ... DNA binding pocket of wild-type DNase I. These ... for DNA. The result is a versatile enzyme ... and an ability to maintain at least 50% ...
Rabbit polyclonal to hnRNP-U...
... formation of a phosphodiester bonds between adjacent ... DNA molecules or between oligonucleotides which are ... 45 - 65?. Tfi DNA Ligase is ... than conventional DNA ligases, Thus, Tfi DNA ...
RABBIT ANTI RHEB (IN) Immunogen: A 15 amino acid peptide located in the central region of human Rheb....
Biology Products: